This regulatory update notes a completed trial on extracorporeal shock wave therapy for shoulder impingement and highlights implications for device sponsors and practicing clinicians.
This release is dated February 15, 2026, and the information derives from a ClinicalTrials.gov record and sponsor disclosures.
The record NCT07410260 describes a study of shoulder impingement in which participants receive a conventional treatment program or an exercise program, alongside extracorporeal shock wave therapy. The interventions listed are conventional treatment program, exercise program, and extracorporeal shock wave therapy. The sponsor for the project is Istinye University, and the trial status is completed in the source record. Readers can view the trial record on ClinicalTrials.gov at the following link: ClinicalTrials.gov record for NCT07410260.
What changed for regulatory observers?
The completion of a trial for a therapy used in musculoskeletal care may influence how regulators view device submissions and post market obligations. Regulators assess trial design and safety signals when a device based therapy is involved. A completed record can guide future discussions on device classification, labeling, and risk management plans. In this context the NCT07410260 record provides a reference point for stakeholders who monitor therapy devices used in shoulder conditions. For readers seeking official details, the record on ClinicalTrials.gov remains the primary source of record and is linked above.
What is Extracorporeal Shock Wave Therapy?
The trial lists extracorporeal shock wave therapy as one of the intervention options. The source text does not specify device settings or protocol parameters. Regulators will expect full method reporting in any subsequent publications and in device submissions that reference this trial.
What is shoulder impingement syndrome?
Shoulder impingement is a condition linked to pain and movement limitation. The trial targets this disorder by combining standard care with a shock wave therapy option. The source notes the condition explicitly but provides no efficacy data within this summary.
What is the trial about and who is affected?
The trial explores three approaches to managing shoulder impingement. The arms include a conventional treatment program, an exercise program, and extracorporeal shock wave therapy. The record identifies Istinye University as the sponsor and marks the study as completed. The source does not publish patient level criteria here, but the implied population includes individuals diagnosed with shoulder impingement syndrome undergoing non surgical care pathways.
From a regulatory lens the trial highlights how combination therapies are tracked in a single protocol. It also underscores the need for transparent reporting of safety events, adherence to protocol, and consistent data capture when a device based therapy is included in a comparative framework. Clinicians and manufacturers should watch for peer reviewed outcomes and any regulatory communications that reference this record.
What interventions were studied?
The three interventions listed in the record are conventional treatment program, exercise program, and extracorporeal shock wave therapy. The conventional and exercise programs are presented as standard care options, while extracorporeal shock wave therapy represents an adjunct or alternative modality within the trial design. There are no efficacy results in the summary, so readers should await full publications to understand comparative effects, safety signals, and practical implications for care pathways.
Regulators may consider how well the trial documents the energy based device use, potential adverse events, operator training, and patient selection. The record also points to the importance of consistent reporting when a device is involved in a multi arm study that includes non device based therapies.
Who sponsored the trial and what does that imply for regulation?
The sponsor listed is Istinye University. In regulatory practice the sponsor is responsible for study conduct, data integrity, and reporting disclosures. The lack of additional details in the record about device manufacturers or regulatory submissions means readers should await further statements or publications for a complete regulatory picture. Nevertheless the sponsor name signals the party responsible for coordinating the study and for providing material to regulatory stakeholders and publication venues.
Regulators may examine sponsor documentation to verify proper trial registration, informed consent practices, safety reporting, and adherence to applicable device testing standards. The connection to a medical device based therapy raises questions about how such a therapy is presented in marketing materials and what claims, if any, might be supported by trial data.
What are the regulatory implications and what comes next?
The regulatory implications depend on the outcomes and the subsequent publishing of results. A completed trial can inform future device submissions or guidance discussions, but the current note does not provide results that would alter immediate regulatory status. Regulators and health care systems should anticipate final data releases and detailed protocol descriptions that address energy delivery, safety events, and patient outcomes. The link to the trial on ClinicalTrials.gov ensures a clear reference point for ongoing regulatory discussions and potential updates to device labeling or usage guidance in musculoskeletal care.
Manufacturers and regulators should monitor for subsequent publications that translate this record into actionable regulatory content. In the context of energy based devices used for shoulder disorders, expected regulatory focus areas include device performance data, risk management documentation, and alignment with identified intended use. Stakeholders should track any updates to guidance that relate to shock wave therapy in musculoskeletal conditions.
What should clinicians know about these findings?
Clinicians should approach this information as a record of ongoing inquiry rather than a statement of proven results. The record confirms a three arm trial design that includes a shock wave therapy option for shoulder impingement. Until peer reviewed results are available, treatment decisions should rely on established clinical guidelines and locally validated protocols. Clinicians may use this record to inform conversations with device makers and institutional review bodies about study designs and data transparency. They should also watch for published outcomes that provide effect estimates and safety data that can influence clinical practice.
FAQ
- 1. What is the purpose of the trial? The trial investigates three approaches to managing shoulder impingement and includes a shock wave therapy option. It does not provide efficacy data in the current note.
- 2. Who funded the trial? Istinye University is listed as the sponsor in the record.
- 3. Where can I find the trial record? The trial record is available on ClinicalTrials.gov under NCT07410260 with the term medical device in the search descriptor.
- 4. Are there results available? The current summary does not include results. Look for peer reviewed publications or regulatory updates for outcomes and safety data.
The completion of this trial marks a milestone in the documentation of energy based therapies for shoulder impingement. Regulators and clinicians should await published results to assess potential labeling, safety considerations, and practical use in care pathways. Meanwhile the record serves as a reference for ongoing regulatory conversations about device based therapies in musculoskeletal care.
Disclaimer: This article is intended for professional readers and is not legal advice. It presents information from the cited trial record and does not constitute regulatory guidance. Users should consult official regulatory sources for up to date requirements.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07410260?term=medical+device